Cozen O’Connor: Class Action & Mass Tort

Class Action & Mass Tort

Recent News:

FDA Alert on Hacking Vulnerability in Heart Defibrillators is Wake-Up Call: Lawyers

John Sullivan was quoted in Law360's recent article on the U.S. Food and Drug Administration's recent safety alert last week about the vulnerability to hacking of up to 750,000 implantable heart defibrillators.

More

Businesses today face an ever-growing threat from class actions and mass torts. These claims have become more frequent and more complex, while their effects on companies can be more devastating than ever, both in terms of potential liability and adverse publicity. Attorneys at Cozen O’Connor have extensive experience in the intricacies of class actions and mass torts and regularly handle these matters in federal and state courts around the country. 

Subject-matter experience

  • Antitrust
  • Securities Fraud
  • Product Liability
  • Consumer Fraud
  • False Advertising
  • Fair Debt Collection
  • Telecomm
  • Wage-and-Hour
  • RICO
  • Environmental and Toxic Tort

Industry experience

  • Banking and Financial Services
  • Construction
  • Drug and Medical Device
  • Food and Beverage
  • Cosmetics
  • Consumer Products
  • Oil and Gas
  • Insurance
  • Healthcare
  • Internet Gaming

Class Action

Cozen O’Connor attorneys understand the procedural, tactical, and reputational issues unique to class action lawsuits. While Cozen O’Connor is known as a trial firm, we aggressively seek to defeat claims at or before the class certification stage. Our primary goal is to achieve early and decisive results while minimizing the disruption for our clients. When necessary, however, we are fully prepared to take any case to trial in any courtroom in America.

Our litigators are particularly mindful of our clients’ business objectives and adept at minimizing the impact of class action claims on business operations. We aim to reduce the burdens on our clients at all turns and work closely with them, where appropriate, to limit and manage the media attention that often comes with high-profile matters. 

Mass Tort

With our national footprint, Cozen O’Connor is well positioned to mount an immediate response to threatened or filed claims anywhere in the United States. As litigation counsel to major corporations in oft-targeted industries, we work with our clients to develop a national litigation strategy, coordinate multi-jurisdictional discovery, select and prepare experts, and identify critical bellwether cases for priority disposition. Our proactive approach often leads to swift and silent resolutions.

Cozen O’Connor attorneys are also proven trial lawyers, having had lead roles in some of the most sprawling mass tort actions to date in defense of tobacco, pharmaceutical, and consumer products manufacturers. Our demonstrated ability to litigate matters to verdict builds our credibility in court and enhances our leverage during discovery, negotiation, mediation, or arbitration. 

Experience

Publications

Personal Jurisdiction through Alter Ego Fails in Illinois

June 29, 2018

John Sullivan, a member in the firm's Commercial Litigation Practice, authored, "Personal Jurisdiction through Alter Ego Fails in Illinois" for the Drug and Device Law Blog.

Events & Seminars

Past Events

In The News

FDA Alert on Hacking Vulnerability in Heart Defibrillators is Wake-Up Call: Lawyers

March 28, 2019

John Sullivan was quoted in Law360's recent article on the U.S. Food and Drug Administration's recent safety alert last week about the vulnerability to hacking of up to 750,000 implantable heart defibrillators.

Cozen O’Connor Continues to Expand its Presence in the Midwest by Adding Business Litigator Kari Berman to its Minneapolis Office

January 07, 2019

Berman brings Nearly Three Decades of Experience Handling Bet-the-Company Disputes

FTC antitrust case against Qualcomm puts business model under microscope

December 30, 2018

David Reichenberg, a member of the firm's Commercial Litigation Department, was quoted in The San Diego Union-Tribune's article, "FTC antitrust case against Qualcomm puts business model under microscope."